These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 30975569)

  • 1. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
    Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
    Vaccine; 2019 May; 37(20):2687-2693. PubMed ID: 30975569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
    Lawrence H; Pick H; Baskaran V; Daniel P; Rodrigo C; Ashton D; Edwards-Pritchard RC; Sheppard C; Eletu SD; Litt D; Fry NK; Rose S; Trotter C; McKeever TM; Lim WS
    PLoS Med; 2020 Oct; 17(10):e1003326. PubMed ID: 33095759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010-2015.
    Silva-Costa C; Brito MJ; Pinho MD; Friães A; Aguiar SI; Ramirez M; Melo-Cristino J; ;
    Emerg Infect Dis; 2018 Jul; 24(7):1307-1314. PubMed ID: 29912700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan.
    Takeuchi N; Naito S; Ohkusu M; Abe K; Shizuno K; Takahashi Y; Omata Y; Nakazawa T; Takeshita K; Hishiki H; Hoshino T; Sato Y; Ishiwada N
    Epidemiol Infect; 2020 Apr; 148():e91. PubMed ID: 32299523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
    Kim JH; Chun BC; Song JY; Kim HY; Bae IG; Kim DM; Choi YH; Jun YH; Choi WS; Kang SH; Kwon HH; Jeong HW; Kee SY; Hur J; Chung JW; Yoon YK; Sohn JW; Yang KS; Kim MJ
    Vaccine; 2019 May; 37(21):2797-2804. PubMed ID: 31005428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom.
    Kandasamy R; Voysey M; Collins S; Berbers G; Robinson H; Noel I; Hughes H; Ndimah S; Gould K; Fry N; Sheppard C; Ladhani S; Snape MD; Hinds J; Pollard AJ
    J Infect Dis; 2020 Mar; 221(8):1361-1370. PubMed ID: 31004136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Prevalence of Vaccine-Type Infections Among Children with Pneumococcal Pneumonia and Effusion After 13-Valent Pneumococcal Conjugate Vaccine Introduction in the Dominican Republic.
    Ahmed SS; Lessa FC; Coradin H; Sánchez J; Carvalho MDG; Soda E; Peña C; Fernández J; Cedano D; Whitney CG; Feris-Iglesias J
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S228-S236. PubMed ID: 34469563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease.
    Principi N; Esposito S
    Expert Rev Vaccines; 2015; 14(10):1359-66. PubMed ID: 26289973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia.
    Forstner C; Kolditz M; Kesselmeier M; Ewig S; Rohde G; Barten-Neiner G; Rupp J; Witzenrath M; Welte T; Pletz MW;
    Vaccine; 2020 Jan; 38(5):1129-1136. PubMed ID: 31761500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the introduction of pneumococcal conjugate vaccines on serotype prevalence in Kuwait and Saudi Arabia.
    Mokaddas EM; Shibl AM; Elgouhary A; Elsobky M
    Vaccine; 2018 Oct; 36(43):6442-6448. PubMed ID: 30194003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M; Christopoulou D; Schmitt HJ
    BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis, Burkina Faso, 2016-2017.
    Soeters HM; Kambiré D; Sawadogo G; Ouédraogo-Traoré R; Bicaba B; Medah I; Sangaré L; Ouédraogo AS; Ouangraoua S; Yaméogo I; Congo-Ouédraogo M; Ky Ba A; Aké F; Srinivasan V; Novak RT; McGee L; Whitney CG; Van Beneden C
    J Infect Dis; 2019 Oct; 220(220 Suppl 4):S253-S262. PubMed ID: 31671444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children.
    Kendall BA; Dascomb KK; Mehta RR; Stockmann C; Mason EO; Ampofo K; Pavia AT; Byington CL
    Vaccine; 2016 Jan; 34(4):474-478. PubMed ID: 26706276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Streptococcus pneumoniae serotype distribution in Vojvodina before the introduction of pneumococcal conjugate vaccines into the National Immunization Program.
    Petrović V; Šeguljev Z; Ristić M; Djekić-Malbaša J; Radosavljević B; Medić D; Mihajlović-Ukropina M; Hadnadjev M; Gajic I; Opavski N
    Srp Arh Celok Lek; 2016; 144(9-10):521-6. PubMed ID: 29653038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution and annual changes in the proportion of Streptococcus pneumoniae serotypes in Japanese adults with pneumococcal pneumonia from 2011 to 2017.
    Noguchi S; Yatera K; Akata K; Chang B; Ikegami H; Hata R; Yamasaki K; Kawanami T; Mukae H
    J Infect Chemother; 2019 Nov; 25(11):925-929. PubMed ID: 31350184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review about Streptococcus Pneumoniae serotype distribution in children in mainland of China before the PCV13 was licensed.
    Lyu S; Hu HL; Yang YH; Yao KH
    Expert Rev Vaccines; 2017 Oct; 16(10):997-1006. PubMed ID: 28745918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
    Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.